Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Next generation immune-checkpoints for cancer therapy.

Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D.

J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. Review.

2.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 May 28. doi: 10.1093/annonc/mdy095. [Epub ahead of print] No abstract available.

PMID:
29846513
3.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 May 28. doi: 10.1093/annonc/mdy096. [Epub ahead of print] No abstract available.

PMID:
29846498
4.

Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S.

JAMA Oncol. 2018 Apr 12. doi: 10.1001/jamaoncol.2018.0219. [Epub ahead of print]

PMID:
29800950
5.

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D.

Oncoimmunology. 2018 Feb 15;7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. eCollection 2018.

6.

Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.

Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, Paioli A, Szucs Z, D'ambrosio L, Scotlandi K, Fagioli F, Asaftei S, Ferrari S.

Acta Oncol. 2018 Mar 13:1-7. doi: 10.1080/0284186X.2018.1449250. [Epub ahead of print]

PMID:
29533113
7.

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment.

Fioramonti M, Fausti V, Pantano F, Iuliani M, Ribelli G, Lotti F, Pignochino Y, Grignani G, Santini D, Tonini G, Vincenzi B.

Sci Rep. 2018 Mar 8;8(1):4177. doi: 10.1038/s41598-018-22469-5.

8.

Different quality of treatment in retroperitoneal sarcomas (RPS) according to hospital-case volume and surgeon-case volume: a retrospective regional analysis in Italy.

Sandrucci S, Ponzetti A, Gianotti C, Mussa B, Lista P, Grignani G, Mistrangelo M, Bertetto O, Di Cuonzo D, Ciccone G.

Clin Sarcoma Res. 2018 Feb 28;8:3. doi: 10.1186/s13569-018-0091-0. eCollection 2018.

9.

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.

Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A.

Eur J Cancer. 2018 Apr;93:28-36. doi: 10.1016/j.ejca.2018.01.071. Epub 2018 Feb 21.

PMID:
29475197
10.

Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma.

Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, Gronchi A; A Collaborative Effort from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Eur J Surg Oncol. 2018 Jun;44(6):810-815. doi: 10.1016/j.ejso.2018.01.086. Epub 2018 Feb 5.

PMID:
29452860
11.

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA.

Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.

12.

EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.

Ferrari S, Bielack SS, Smeland S, Longhi A, Egerer G, Sundby Hall K, Donati D, Kevric M, Brosjö O, Comandone A, Werner M, Monge O, Palmerini E, Berdel WE, Bjerkehagen B, Paioli A, Lorenzen S, Eriksson M, Gambarotti M, Tunn PU, Jebsen NL, Cesari M, von Kalle T, Ferraresi V, Schwarz R, Bertulli R, Kasparek AK, Grignani G, Krasniqi F, Sorg B, Hecker-Nolting S, Picci P, Reichardt P.

Tumori. 2018 Jan-Feb;104(1):30-36. doi: 10.5301/tj.5000696.

PMID:
29218692
13.

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.

Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.

Crit Rev Oncol Hematol. 2017 Oct;118:1-6. doi: 10.1016/j.critrevonc.2017.06.006. Epub 2017 Jul 15. Review.

PMID:
28917265
14.

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S.

J Clin Oncol. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.

PMID:
28854066
15.

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.

Br J Cancer. 2017 Oct 24;117(9):1278-1285. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29.

16.

Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, Grignani G, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D.

Mol Med. 2017 Aug 9;23. doi: 10.2119/molmed.2017.00084. [Epub ahead of print]

17.

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study.

Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra M, Mungul A, Manson SC, Sanfilippo R.

Acta Oncol. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 2017 Jul 19.

PMID:
28723233
18.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P.

Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Erratum in: Lancet Oncol. 2018 Feb;19(2):e78.

PMID:
28651927
19.

Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.

Luksch R, Grignani G, D'Angelo P, Prete A, Puma N, Podda M, Casanova M, Ferrari A, Morosi C, Fagioli F, Aglietta M, Ferrari S, Picci P, Massimino M.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26650. Epub 2017 Jun 14.

PMID:
28612488
20.

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG.

Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Erratum in: Lancet Oncol. 2017 Jun;18(6):e301.

PMID:
28499583
21.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G.

Mol Cancer. 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5.

22.

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G.

Eur J Cancer. 2017 Jun;78:122-132. doi: 10.1016/j.ejca.2017.03.025. Epub 2017 Apr 24.

PMID:
28448856
23.

Alpha-fetoprotein elevation in NUT midline carcinoma: a case report.

D'Ambrosio L, Palesandro E, Moretti M, Pelosi G, Fabbri A, Carnevale Schianca F, Aglietta M, Grignani G.

BMC Cancer. 2017 Apr 13;17(1):266. doi: 10.1186/s12885-017-3262-0.

24.

How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, Casali PG, Picci P.

Clin Sarcoma Res. 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. eCollection 2017.

25.

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.

Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, Gronchi A, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, D'Ambrosio L, Willegger M, Scoccianti G, Ferrari S.

Eur J Cancer. 2017 Mar;74:9-16. doi: 10.1016/j.ejca.2016.12.016. Epub 2017 Feb 3.

PMID:
28167373
26.

Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.

Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G.

Mol Cancer Res. 2017 May;15(5):553-562. doi: 10.1158/1541-7786.MCR-16-0376. Epub 2017 Jan 27.

27.

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M.

Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466. doi: 10.1016/j.bbmt.2016.12.636. Epub 2016 Dec 27.

28.

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.

Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B.

Acta Oncol. 2017 Jan;56(1):88-92. doi: 10.1080/0284186X.2016.1234068. Epub 2016 Nov 14.

PMID:
27838944
29.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.

30.

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P.

Ann Oncol. 2016 Dec;27(12):2283-2288. doi: 10.1093/annonc/mdw430. Epub 2016 Oct 11.

PMID:
27733375
31.

Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report.

Fenocchio E, Depetris I, Campanella D, Garetto L, Schianca FC, Galizia D, Grignani G, Aglietta M, Leone F.

BMC Cancer. 2016 Oct 12;16(1):793.

32.

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.

Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D.

J Transl Med. 2016 May 5;14(1):119. doi: 10.1186/s12967-016-0872-2.

33.

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S, Grignani G, Tamburini A, Pollack SM, Picci P, Ferrari S.

BMC Cancer. 2016 Apr 20;16:280. doi: 10.1186/s12885-016-2312-3.

34.

Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma.

Apice G, Pizzolorusso A, Di Maio M, Grignani G, Gebbia V, Buonadonna A, De Chiara A, Fazioli F, De Palma G, Galizia D, Arcara C, Mozzillo N, Perrone F.

Sarcoma. 2016;2016:6862090. doi: 10.1155/2016/6862090. Epub 2016 Feb 25.

35.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR.

Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.

PMID:
26874885
36.

Trabectedin clinical cases: use according to indication in diverse clinical scenarios.

Grignani G, Martín-Broto J, Schuler M, Reichardt P.

Future Oncol. 2015;11(11 Suppl):15-24. doi: 10.2217/fon.15.76.

PMID:
26043311
37.

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM.

BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1.

38.

Adoptive immunotherapy against sarcomas.

Mesiano G, Leuci V, Giraudo L, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, Capellero S, Pignochino Y, Grignani G, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2015 Apr;15(4):517-28. doi: 10.1517/14712598.2015.987121. Epub 2014 Dec 16. Review.

PMID:
25516119
39.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group.

Lancet Oncol. 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11.

40.

Anticoagulation for central venous catheters in patients with cancer.

D'Ambrosio L, Aglietta M, Grignani G.

N Engl J Med. 2014 Oct 2;371(14):1362-3. doi: 10.1056/NEJMc1408861. No abstract available.

41.

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.

Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N.

Eur J Cancer. 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.

PMID:
25269954
42.

Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.

Rota Scalabrini D, Caravelli D, Carnevale Schianca F, D'Ambrosio L, Tolomeo F, Boccone P, Manca A, De Rosa G, Nuzzo A, Aglietta M, Grignani G.

BMC Res Notes. 2014 Aug 14;7:529. doi: 10.1186/1756-0500-7-529. Review.

43.

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma.

Sangiolo D, Mesiano G, Gammaitoni L, Aglietta M, Grignani G.

Oncoimmunology. 2014 Mar 17;3:e28269. eCollection 2014.

44.

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.

Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'Aglio C, D'Ambrosio L, Pisacane A, Sarotto I, Miano S, Ferrero I, Carnevale-Schianca F, Pignochino Y, Sassi F, Bertotti A, Piacibello W, Fagioli F, Aglietta M, Grignani G.

Cancer Res. 2014 Jan 1;74(1):119-29. doi: 10.1158/0008-5472.CAN-13-1559. Epub 2013 Dec 19.

45.

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.

Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; ISG and FSG.

Ann Oncol. 2014 Mar;25(3):578-83. doi: 10.1093/annonc/mdt485. Epub 2013 Dec 9.

46.

Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.

Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarria P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P, Casali PG.

Eur J Cancer. 2014 Mar;50(4):784-92. doi: 10.1016/j.ejca.2013.11.021. Epub 2013 Dec 5.

PMID:
24316063
47.
48.

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.

Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, Caravelli D, Giacone E, Venesio T, Balsamo A, Pignochino Y, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2013 Aug 15;19(16):4347-58. doi: 10.1158/1078-0432.CCR-13-0061. Epub 2013 Jun 21.

49.

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G.

Clin Cancer Res. 2013 Apr 15;19(8):2117-31. doi: 10.1158/1078-0432.CCR-12-2293. Epub 2013 Feb 22.

50.

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.

Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali PG.

Ann Oncol. 2013 Mar;24(3):817-23. doi: 10.1093/annonc/mds501. Epub 2012 Oct 30.

PMID:
23110811

Supplemental Content

Loading ...
Support Center